We leveraged our 20 years of epigenomic expertise to help Universal Diagnostics (UDx) develop a customized early-detection workflow for colorectal cancer (CRC), integrating liquid biopsies with DNA methylation technologies for biomarker discovery and validation.
Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in realtime in the risk population.
Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarker using our WGBS/EM-seq service.
Once a pool of potential biomarkers was available, the best performers were identified and validated using our custom Targeted Methyl-seq service.
Kristi Kruusmaa
Chief Scientific Officer
Universal Diagnostics
